



Celebrating 22 Years of HepaRG®: A Landmark in Hepatic Research

We are proud to celebrate the 22nd anniversary of the first publication featuring HepaRG®, titled Infection of a Human Hepatoma Cell Line by Hepatitis B Virus, by Gripon, P., in 2002. Biopredic played a key role in this groundbreaking study, and since then, we have proudly supported the success of HepaRG®. In 2007, we became the exclusive licensee of Inserm, the owner of the HepaRG® material, and have continued this journey ever since.

Over the years, more than 1,000 publications in diverse applications have highlighted the significant impact HepaRG® has had in hepatic research.

Thank you for being part of this remarkable journey, and if you haven't already, we warmly invite you to join the growing community!

A look back at the HepaRG® legacy:

- Nickname: The HepaRG® model is proudly known as the "surrogate for human hepatocytes" within the scientific community.
- Global reach: HepaRG® has been used in research across the globe.
- What users are saying:

"The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in humans." — Andersson, T.B., 2012.

"HepaRG is becoming increasingly popular because of its perceived closer resemblance to human hepatocytes."- Stanley, L.A., 2022.

"Three-dimensional HepaRG spheroids are a powerful tool for in vitro studies." — Horn, G., 2023.

"Owing to its differentiation and biotransformation capacities and its genetic stability, the human HepaRG cell model has numerous advantages for studying hepatotoxic effects of compounds." — Dubreil, E., 2024.

"3D HepaRG spheroids can enhance the performance of in vitro genotoxicity testing by generating data that are more relevant to the human metabolic condition." — Seo, J-E., 2022.

"3D HepaRG spheroids maintain a stable phenotype over multiple weeks, support highly reproducible tissue-like architectures and model pharmacologically- and environmentally important hepatic receptor pathways (ie AhR, CAR, and PXR) analogous to primary human hepatocyte cultures." - Ramaiahgari SC, Ferguson SS., 2017.

"Among all in vitro models, differentiated HepaRG cells are currently the closest to PHHs. " — Dubois-Pot-Schneider H., Corlu, A., 2022.

"In the assay to profile the induction of CYP1A2, CYP2B6 and CYP3A4 mRNA levels, both human hepatocytes and HepaRG cells demonstrated similar trend in mRNA induction, suggesting that HepaRG cells would be good alternative cells to human cryopreserved hepatocytes to determine the relative induction capacity of drugs." Sugiyama I., Hirota T., 2016.



Biopredic Parc d'Affaires La Bretèche Biopredic 35760 Saint Grégoire